Removing One Thyroid Lobe to Treat Sporadic Medullary Thyroid Cancer
Tests removing one thyroid lobe and nearby lymph nodes in sporadic medullary thyroid cancer.
Plain-language title generated from the registry record
Registry title: STAGE-MTC Trial Thyroid Lobectomy With Ipsilateral Central Neck Dissection
Key facts
- Where
- Los Angeles, United StatesSee the site
Where in United States
- UCLA / Jonsson Comprehensive Cancer CenterLos Angeles, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Jonsson Comprehensive Cancer Center
- Trial code
- NCT07612293
- Record updated
- 19 October 2026
- Original description
This clinical trial studies how well thyroid lobectomy with ipsilateral central neck dissection works to treat medullary thyroid cancer (MTC) in patients without a germline RET mutation (sporadic). Currently, sporadic and germline RET (rearranged during transfection) mutation positive MTCs that are limited to the thyroid are managed in the same way, complete surgical removal of the entire thyroid gland (total thyroidectomy) with surgical removal of lymph nodes and other tissues on both sides of the neck (bilateral central neck dissection). Total thyroidectomy and bilateral central neck dissection carry a high risk of complications, and total thyroidectomy requires patients to take lifelong thyroid hormone replacement therapy, which can impact quality of life. Research has shown that patients with sporadic MTC do not have a high risk of developing MTC in the remaining normal thyroid tissue and that they may be able to be managed differently than patients with germline RET mutations. Thyroid lobectomy with ipsilateral central neck dissection is a surgical procedure which removes only the lobe of the thyroid gland that is affected by cancer as well as the lymph nodes and other tissues from the affected side of the neck. Thyroid lobectomy with ipsilateral central neck dissection may be a safer, more tolerable, and/or more effective way to treat sporadic MTC.Read full original descriptionShow less
STAGE-MTC Trial Thyroid Lobectomy With Ipsilateral Central Neck Dissection for the Treatment of Sporadic Medullary Thyroid Cancer, STAGE-MTC Trial
This clinical trial studies how well thyroid lobectomy with ipsilateral central neck dissection works to treat medullary thyroid cancer (MTC) in patients without a germline RET mutation (sporadic). Currently, sporadic and germline RET (rearranged during transfection) mutation positive MTCs that are limited to the thyroid are managed in the same way, complete surgical removal of the entire thyroid gland (total thyroidectomy) with surgical removal of lymph nodes and other tissues on both sides of the neck (bilateral central neck dissection). Total thyroidectomy and bilateral central neck dissection carry a high risk of complications, and total thyroidectomy requires patients to take lifelong thyroid hormone replacement therapy, which can impact quality of life. Research has shown that patients with sporadic MTC do not have a high risk of developing MTC in the remaining normal thyroid tissue and that they may be able to be managed differently than patients with germline RET mutations. Thyroid lobectomy with ipsilateral central neck dissection is a surgical procedure which removes only the lobe of the thyroid gland that is affected by cancer as well as the lymph nodes and other tissues from the affected side of the neck. Thyroid lobectomy with ipsilateral central neck dissection may be a safer, more tolerable, and/or more effective way to treat sporadic MTC.
Inclusion: Male or female ≥ 18 years of age at time of diagnosis; Documentation of a medullary thyroid cancer diagnosis as evidenced by:; Thyroid fine needle aspiration biopsy with cytologist consistent with medullary thyroid cancer; Indeterminate cytology from thyroid fine needle aspiration with elevated serum calcitonin OR thyroid molecular testing consistent with medullary thyroid cancer; Written informed consent obtained from participant or participant's legal representative and ability for participant to comply with the requirements of the study; Appropriate candidate for thyroid lobectomy and/or total thyroidectomy.
Exclusion: Indication for total thyroidectomy unrelated to medullary thyroid cancer:; Graves' disease; Symptomatic multinodular goiter; Contralateral symptomatic benign nodules; Ultrasound findings consistent with:; Cervical lymphadenopathy involving lateral neck or contralateral central neck; Suspicious thyroid nodules > 1 cm that are Thyroid Imaging Reporting and Data Systems 2 (TIRADS2) or higher without fine needle aspiration (FNA); Pure cystic and spongiform nodules do not require FNA; Patients with nodules that meet criteria above can elect to undergo FNA, and may enroll in study if benign cytology is noted; Identification of germline RET mutation on preoperative genetic testing.